6 Biotechnology Stocks to Sell Now

by Portfolio Grader | January 1, 2014 7:45 am

The overall ratings of six biotechnology stocks are down on Portfolio Grader[1] this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, TESARO, Inc. (TSRO[2]) falls to a D (“sell”), worse than last week’s grade of C (“hold”). In Portfolio Grader’s specific subcategories of Equity and Cash Flow, TSRO also gets F’s. The stock price has dropped 28.1% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of TSRO stock[3].

Trius Therapeutics, Inc. (TSRX[4]) gets weaker ratings this week as last week’s C drops to a D. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. For a full analysis of TSRX stock, visit Portfolio Grader[5].

Protalix Biotherapeutics, Inc.’s (PLX[6]) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Protalix BioTherapeutics is a biotechnology company that has developed plant cell culture technology and a bioreactor system. The stock gets F’s in Earnings Revisions and Sales Growth. For more information, get Portfolio Grader’s complete analysis of PLX stock[7].

The rating of Array BioPharma (ARRY[8]) slips from a C to a D. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. The stock gets F’s in Cash Flow and Sales Growth. The stock price has fallen 19.5% over the past month. To get an in-depth look at ARRY, get Portfolio Grader’s complete analysis of ARRY stock[9].

Regeneron Pharmaceuticals, Inc. (REGN[10]) earns a D this week, falling from last week’s grade of C. Regeneron Pharmaceuticals researches, develops and commercializes therapeutics to treat human disorders and conditions. The stock also gets an F in Earnings Momentum. Investors seem to agree with the downgrade and have pushed down the share price 6.6% over the past month. The stock’s trailing PE Ratio is 43.00. For a full analysis of REGN stock, visit Portfolio Grader[11].

Discovery Laboratories, Inc. (DSCO[12]) gets weaker ratings this week as last week’s C drops to a D. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. Wall Street appears to agree with the stock downgrade, with share prices dropping 5.5% over the past month. For more information, get Portfolio Grader’s complete analysis of DSCO stock[13].

Louis Navellier’s proprietary Portfolio Grader[14] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[15].

Source URL: https://investorplace.com/2014/01/6-biotechnology-stocks-to-sell-now-tsro-tsrx-plx/

---